Sign In
Buy CANF
$3.15
-0.130 (-3.96%)
At Close: Jul 31, 2026
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th
11:00am, Wednesday, 03'rd Jun 2020
Can-Fite BioPharma to Hold Investor Webinar and Q&A; Session with CEO on June 2nd
Can Fite Biofarma shares are trading lower after the company reported worse-than-expected Q1 sales results.
01:06pm, Monday, 01'st Jun 2020Can-Fite Biopharma Q1 EPS $(0.03) Beats $(0.66) Estimate, Sales $198.00K Miss $1.18M Estimate
11:09am, Monday, 01'st Jun 2020Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
11:00am, Monday, 01'st Jun 2020
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
Can-Fite BioPharma Ltd. to Host Earnings Call
10:30am, Monday, 01'st Jun 2020
NEW YORK, NY / ACCESSWIRE / June 1, 2020 / Can-Fite BioPharma Ltd. (AMEX:CANF) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on June 1, 2020 at 8:30 AM
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020
11:00am, Thursday, 28'th May 2020
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
11:00am, Thursday, 21'st May 2020
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
